Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-inactivated Adlercreutzia equolifaciens
- Development stage
- Preclinical
- Lead developer
- Peking University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Heat-inactivated *Adlercreutzia equolifaciens* is a postbiotic (also known as a paraprobiotic) preparation consisting of non-viable cells of the Gram-positive bacterium *A. equolifaciens*. This preparation is primarily utilized in preclinical research to investigate the metabolic effects of the species, particularly its role in mediating the relationship between nicotine consumption and weight loss. While live *A. equolifaciens* has been shown to reduce obesity by degrading gut nicotine and subsequently modulating polyunsaturated fatty acid (PUFA) levels and adipose tissue thermogenesis, the heat-inactivated version is often used as a control to demonstrate that these specific enzymatic activities require viable bacteria. However, as a postbiotic, it remains a subject of interest for its potential to influence the gut microbiota composition and host immune signaling through heat-stable cellular components. It is currently in the early stages of research as a potential microbial therapy for metabolic disorders.
- Other names
- heat-killed Adlercreutzia equolifaciensHK-A. equolifaciensinactivated Adlercreutzia equolifaciens
Beyond the preview
Go deeper on heat-inactivated Adlercreutzia equolifaciens.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-inactivated Adlercreutzia equolifaciens.